カルシウム拮抗薬の世界市場レポート 2024年

カルシウム拮抗薬市場規模は近年力強く成長しています。2023年の147億2,000万米ドルから2024年には157億5,000万米ドルに、CAGR7.0％で拡大します。カルシウム拮抗薬の使用において過去期間に観察された成長は、心血管疾患の発生率の増加、高齢化人口の増加、より良い治療オプションにつながる医学研究の進歩、ライフスタイルパターンの変化、心血管の健康に対する個人の意識の高まりなど、さまざまな要因に起因しています。

カルシウム拮抗薬市場の成長は、心血管疾患の有病率の増加によって促進されると予測されます。心臓や血管に影響を及ぼす心血管疾患は、より一般的になっており、カルシウム拮抗薬（CCBs）などの介入に対する需要の高まりにつながっています。これらの薬剤は、心不全や脳卒中のリスクを軽減するために使用されます。米国心臓病学会の2022年8月の報告では、米国では2025年から2060年にかけて心血管危険因子が増加すると予測されています。特に糖尿病は39.3％、脂質異常症は27.6％、高血圧は25.1％、肥満は18.3％増加すると予測されています。脳卒中、心不全、虚血性心疾患、心臓発作を含む心血管系疾患の割合も大幅に増加すると予想されています。このような心血管疾患の急増が、カルシウム拮抗薬市場の成長を牽引しています。

2023年のカルシウム拮抗薬市場では北米が最大地域でした。カルシウム拮抗薬市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 カルシウム拮抗薬市場の特徴

第3章 カルシウム拮抗薬市場の動向と戦略

第4章 カルシウム拮抗薬市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界のカルシウム拮抗薬市場の規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 カルシウム拮抗薬市場セグメンテーション

• 世界のカルシウム拮抗薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ジヒドロピリジン
• ベンゾチゼピン
• フェニルアルキルアミン
• その他
• 世界のカルシウム拮抗薬市場、疾患適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 高血圧
• 胸痛
• 不整脈
• 世界のカルシウム拮抗薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• その他
• 世界のカルシウム拮抗薬市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 在宅ケア
• 専門クリニック
• その他のエンドユーザー

第7章 カルシウム拮抗薬市場の地域および国分析

• 世界のカルシウム拮抗薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界のカルシウム拮抗薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋のカルシウム拮抗薬市場

第9章 中国のカルシウム拮抗薬市場

第10章 インドのカルシウム拮抗薬市場

第11章 日本のカルシウム拮抗薬市場

第12章 オーストラリアのカルシウム拮抗薬市場

第13章 インドネシアのカルシウム拮抗薬市場

第14章 韓国のカルシウム拮抗薬市場

第15章 西欧のカルシウム拮抗薬市場

第16章 英国のカルシウム拮抗薬市場

第17章 ドイツのカルシウム拮抗薬市場

第18章 フランスのカルシウム拮抗薬市場

第19章 イタリアのカルシウム拮抗薬市場

第20章 スペインのカルシウム拮抗薬市場

第21章 東欧のカルシウム拮抗薬市場

第22章 ロシアのカルシウム拮抗薬市場

第23章 北米のカルシウム拮抗薬市場

第24章 米国のカルシウム拮抗薬市場

第25章 カナダのカルシウム拮抗薬市場

第26章 南米カルシウム拮抗薬市場

第27章 ブラジルのカルシウム拮抗薬市場

第28章 中東のカルシウム拮抗薬市場

第29章 アフリカのカルシウム拮抗薬市場

第30章 カルシウム拮抗薬市場の競合情勢と企業プロファイル

• カルシウム拮抗薬市場の競合情勢
• カルシウム拮抗薬市場の企業プロファイル
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bausch Health Companies Inc.
  • Lupin Pharmaceuticals Inc.

第31章 世界のカルシウム拮抗薬市場の競合ベンチマーキング

第32章 世界のカルシウム拮抗薬市場競争ダッシュボード

第33章 カルシウム拮抗薬市場における主要な合併と買収

第34章 カルシウム拮抗薬市場の将来の見通しと可能性分析

第35章 付録

“Calcium Channel Blocker Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on calcium channel blocker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for calcium channel blocker? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The calcium channel blocker market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: Dihydropyridine; Benzothizepine; Phenylalkylamine; Other Drug Classes
• 2) By Disease Indications: Hypertension; Chest Pain; Arrhythmias
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Novartis AG; Bausch Health Companies Inc.; Lupin Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Calcium channel blockers are medications designed to inhibit calcium from entering the muscle cells in the heart and blood vessels. They are commonly used in the treatment of various conditions such as high blood pressure, angina (chest pain), and irregular heart rhythms.

These drugs belong to different classes including dihydropyridine, benzothiazepine, phenylalkylamine, and others. Dihydropyridines specifically function by blocking calcium channels present in the muscle cells of the heart and arterial blood vessels, thereby reducing the influx of calcium ions into these cells. These medications are indicated for conditions such as hypertension (high blood pressure), chest pain, and certain types of arrhythmias. They are typically administered orally, through parenteral routes, or by other methods, and are utilized by hospitals, homecare settings, specialty clinics, and other end-users for medical purposes.

The calcium channel blocker market research report is one of a series of new reports from The Business Research Company that provides calcium channel blocker market statistics, including calcium channel blocker industry global market size, regional shares, competitors with calcium channel blocker market share, detailed calcium channel blocker market segments, market trends, and opportunities, and any further data you may need to thrive in the calcium channel blocker industry. This calcium channel blocker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The calcium channel blocker market size has grown strongly in recent years. It will grow from $14.72 billion in 2023 to $15.75 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period within the usage of calcium channel blockers can be attributed to various factors, including an increased incidence of cardiovascular diseases, a growing aging population, advancements in medical research leading to better treatment options, shifts in lifestyle patterns, and heightened awareness among individuals about cardiovascular health.

The calcium channel blocker market size is expected to see strong growth in the next few years. It will grow to $20.64 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. Anticipated growth in the upcoming period within the usage of calcium channel blockers can be linked to several key factors, notably the escalating global burden of cardiovascular diseases, the trend towards personalized medicine, improved access to healthcare services, expansions in the range of indications for these medications, and regulatory approvals driving market expansions. Major trends expected in the forecast period encompass overall market growth, technological advancements in treatment methods, shifts in the regulatory landscape affecting these medications, competitive analysis within the pharmaceutical industry, considerations of patient preferences, and heightened awareness among patients regarding treatment options.

The growth of the calcium channel blocker market is anticipated to be propelled by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases, affecting the heart or blood vessels, have become more prevalent, leading to a heightened demand for interventions such as calcium channel blockers (CCBs). These medications are employed to reduce the risk of heart failure and stroke. An August 2022 report from the American College of Cardiology predicts a rise in cardiovascular risk factors in the United States between 2025 and 2060. Notably, diabetes is projected to increase by 39.3%, dyslipidemia by 27.6%, hypertension by 25.1%, and obesity by 18.3%. Substantial increases are also expected in cardiovascular disease rates, including stroke, heart failure, ischemic heart disease, and heart attack. This surge in cardiovascular conditions is driving the growth of the calcium channel blocker market.

The growth of the calcium channel blocker market is further supported by the increasing healthcare expenditure. Healthcare expenditure refers to the total resources allocated and spent on healthcare services and related activities within a specific timeframe. Elevated healthcare spending contributes to a favorable environment for the calcium channel blocker market, facilitating better access, affordability, research and development, and overall patient care. According to the 2021-2030 National Health Expenditure report by the Centers for Medicare & Medicaid Services, national health spending in the United States is expected to increase by an average of 5.1% annually between 2021 and 2030, reaching nearly $6.8 trillion. The report also forecasts a 7.2% annual increase in Medicare spending and a 5.6% annual rise in Medicaid spending during the same period, highlighting the significant role of healthcare expenditure in driving the growth of the calcium channel blocker market.

Product innovation emerges as a key trend in the calcium channel blocker market, with major companies emphasizing the development of innovative products to maintain their market position. For example, in June 2022, CMP Pharma, a US-based pharmaceutical manufacturing company, introduced Norliqva, the first and only oral liquid solution of the besylate salt of amlodipine-an extended-release calcium channel blocker. Norliqva addresses the challenges associated with crushing or synthesizing amlodipine tablets, ensuring uniform dosing and bioequivalence. This innovative product caters to patients who require amlodipine but face difficulties with swallowing or are unable to swallow. The focus on product innovation is a testament to the dynamic nature of the calcium channel blocker market and the commitment of major companies to meeting evolving healthcare needs.

Major companies within the calcium channel blocker market are strategically developing innovative products, specifically tablets tailored for the treatment of Pulmonary Arterial Hypertension (PAH). These tablets serve as oral pharmaceutical formulations designed to address the unique medical condition of PAH. In May 2022, Zydus, an India-based pharmaceutical company, achieved approval from the US Food and Drug Administration (FDA) for Selexipag tablets. Selexipag is indicated for use in adults to manage Pulmonary Arterial Hypertension, with the goal of delaying disease progression and reducing the likelihood of hospitalization associated with PAH. As a prostacyclin receptor agonist, this medication contributes to the comprehensive management of PAH.

In September 2021, Azurity Pharmaceuticals Inc., a US-based specialty pharmaceutical company, executed the acquisition of Arbor Pharmaceuticals LLC in. The acquisition, undertaken for an undisclosed amount, has positioned Azurity Pharmaceuticals Inc. to establish a prominent business that delivers cutting-edge, high-value pharmaceutical products. Arbor Pharmaceuticals LLC, the acquired company, specializes in providing calcium channel blocking agents, aligning with the broader goals of Azurity Pharmaceuticals Inc. to cater to the specific needs of patients with underserved illnesses. This strategic acquisition reinforces Azurity Pharmaceuticals Inc.'s commitment to advancing its product portfolio and addressing critical medical conditions within the calcium channel blocker market.

Major companies operating in the calcium channel blocker market report are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Mylan N.V., Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Dragerwerk AG & Co. KGaA, Fresenius Kabi AG, General Electric Company, Koninklijke Philips N.V., MAQUET Holding B.V. & Co. KG, Medtronic plc, AKAS Medical, Smiths Medical International Limited .

North America was the largest region in the calcium channel blocker market in 2023. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the calcium channel blocker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcium channel blocker market consists of sales of amlodipine, nicardipine, isradipine, diltiazem, and verapamil drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Calcium Channel Blocker Market Characteristics

3. Calcium Channel Blocker Market Trends And Strategies

4. Calcium Channel Blocker Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Calcium Channel Blocker Market Size and Growth

• 5.1. Global Calcium Channel Blocker Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Calcium Channel Blocker Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Calcium Channel Blocker Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Calcium Channel Blocker Market Segmentation

• 6.1. Global Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Dihydropyridine
• Benzothizepine
• Phenylalkylamine
• Other Drug Classes
• 6.2. Global Calcium Channel Blocker Market, Segmentation By Disease Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hypertension
• Chest Pain
• Arrhythmias
• 6.3. Global Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Route Of Administration
• 6.4. Global Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users

7. Calcium Channel Blocker Market Regional And Country Analysis

• 7.1. Global Calcium Channel Blocker Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Calcium Channel Blocker Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Calcium Channel Blocker Market

• 8.1. Asia-Pacific Calcium Channel Blocker Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Calcium Channel Blocker Market

• 9.1. China Calcium Channel Blocker Market Overview
• 9.2. China Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Calcium Channel Blocker Market

• 10.1. India Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Calcium Channel Blocker Market

• 11.1. Japan Calcium Channel Blocker Market Overview
• 11.2. Japan Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Calcium Channel Blocker Market

• 12.1. Australia Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Calcium Channel Blocker Market

• 13.1. Indonesia Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Calcium Channel Blocker Market

• 14.1. South Korea Calcium Channel Blocker Market Overview
• 14.2. South Korea Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Calcium Channel Blocker Market

• 15.1. Western Europe Calcium Channel Blocker Market Overview
• 15.2. Western Europe Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Calcium Channel Blocker Market

• 16.1. UK Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Calcium Channel Blocker Market

• 17.1. Germany Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Calcium Channel Blocker Market

• 18.1. France Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Calcium Channel Blocker Market

• 19.1. Italy Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Calcium Channel Blocker Market

• 20.1. Spain Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Calcium Channel Blocker Market

• 21.1. Eastern Europe Calcium Channel Blocker Market Overview
• 21.2. Eastern Europe Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Calcium Channel Blocker Market

• 22.1. Russia Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Calcium Channel Blocker Market

• 23.1. North America Calcium Channel Blocker Market Overview
• 23.2. North America Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Calcium Channel Blocker Market

• 24.1. USA Calcium Channel Blocker Market Overview
• 24.2. USA Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Calcium Channel Blocker Market

• 25.1. Canada Calcium Channel Blocker Market Overview
• 25.2. Canada Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Calcium Channel Blocker Market

• 26.1. South America Calcium Channel Blocker Market Overview
• 26.2. South America Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Calcium Channel Blocker Market

• 27.1. Brazil Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Calcium Channel Blocker Market

• 28.1. Middle East Calcium Channel Blocker Market Overview
• 28.2. Middle East Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Calcium Channel Blocker Market

• 29.1. Africa Calcium Channel Blocker Market Overview
• 29.2. Africa Calcium Channel Blocker Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Calcium Channel Blocker Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Calcium Channel Blocker Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Calcium Channel Blocker Market Competitive Landscape And Company Profiles

• 30.1. Calcium Channel Blocker Market Competitive Landscape
• 30.2. Calcium Channel Blocker Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. GlaxoSmithKline plc
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bausch Health Companies Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Lupin Pharmaceuticals Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Calcium Channel Blocker Market Competitive Benchmarking

32. Global Calcium Channel Blocker Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Calcium Channel Blocker Market

34. Calcium Channel Blocker Market Future Outlook and Potential Analysis

• 34.1 Calcium Channel Blocker Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Calcium Channel Blocker Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Calcium Channel Blocker Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer